Welcome to our dedicated page for Venus Concept news (Ticker: VERO), a resource for investors and traders seeking the latest updates and insights on Venus Concept stock.
Venus Concept Inc. (NASDAQ: VERO) is a medical aesthetic technology company whose news flow reflects both its product developments and its capital and strategic actions. The company describes itself as a global medical aesthetic technology leader with a portfolio of minimally invasive and non-invasive systems for body, face, skin and hair restoration applications. Its updates often highlight device platforms such as Venus Versa, Venus Legacy, Venus Bliss, Venus Viva, Venus Epileve, AI.ME and, more recently, the next-generation Venus NOVA platform.
On this news page, readers can follow VERO news related to quarterly financial results, regulatory milestones, financing transactions and strategic portfolio moves. Recent press releases have covered second and third quarter financial results, including revenue by region and product category, gross profit trends, operating expenses and operating loss. Management commentary in these releases discusses the performance of energy-based device revenues, the impact of macroeconomic conditions on capital equipment sales, and the company’s efforts in cost containment and operational streamlining.
Venus Concept’s news also includes regulatory and product announcements, such as FDA 510(k) clearance for Venus NOVA, a multi-application platform for non-invasive body and skin treatments that integrates Adaptive EMS, proprietary (MP)² technology and Advanced VariPulse. In addition, the company reports on capital structure and financing events, including registered direct offerings of common stock, private placements of warrants, bridge loan drawdowns and debt-to-equity exchanges of subordinated convertible notes into Series Y Preferred Stock.
Another recurring theme in VERO news is the company’s strategic initiatives, notably the definitive agreement to sell its Venus Hair business, which includes NeoGraft and the ARTAS iX Robotic Hair Restoration system, to MHG Co. Ltd. Investors and observers can use this page to monitor how these developments evolve over time, from transaction announcements and court-related updates to subsequent financial disclosures.
Venus Concept (NASDAQ: VERO) announced its intent to voluntarily delist from the Nasdaq Capital Market and deregister its common stock with the SEC. The company plans to file a Form 25 on or about January 30, 2026, expects the last Nasdaq trading day to be on or about February 6, 2026, and intends to file a Form 15 on or about February 9, 2026, upon which periodic SEC reporting (Forms 10-K, 10-Q, 8-K) will be suspended.
The Board said delisting reflects a judgment that ongoing SEC reporting costs outweigh benefits and that reduced compliance costs should help execution of the company’s turnaround plan; the company also cited continued collaboration with Madryn Asset Management.
Venus Concept (NASDAQ: VERO) reported Q3 2025 revenue of $13.8M, down 8% year-over-year, with EBD systems sales $9.6M (up 2% YoY). The company posted a GAAP net loss of $22.5M and an Adjusted EBITDA loss of $7.8M. Gross margin declined to 64.0% from 66.1% due mainly to U.S. tariffs and lower volume. Cash and restricted cash totaled about $5.9M and total debt obligations were approximately $30.1M as of Sept 30, 2025.
Key corporate actions include debt-to-equity exchanges ($6.5M on June 30 and $11.5M on Sept 30) reducing debt versus Dec 31, 2024, and FDA 510(k) clearance for Venus NOVA on Nov 10, 2025. The planned sale of the Venus Hair Business to MHG remains delayed and the company has sought assistance from the Delaware Court of Chancery.
Venus Concept (NASDAQ: VERO) received FDA 510(k) clearance for Venus NOVA, its next‑generation multi‑application platform for non‑invasive body, face, and skin treatments.
Key features include FlexMAX EMS (up to 100,000 contractions per session), (MP)² RF+PEMF, Advanced VariPulse™, Automatic Temperature Control, and IoT connectivity via Venus Connect. U.S. commercial availability is planned for December 2025 with global rollout in 2026. The launch is described as the first product from the company’s new R&D strategy and is supported by the Venus Jumpstart Program and financial backing from Madryn Asset Management.
Venus Concept (NASDAQ: VERO) announced that on September 30, 2025 it exchanged the full $11.48 million balance of subordinated convertible notes held by Madryn for 545,335 shares of Series Y preferred stock. Post-transaction, total debt obligations are approximately $30.1 million, a 24% reduction from $39.7 million as of December 31, 2024. Management says the exchange improves financial flexibility to support its transformation plan and return to growth.
Venus Concept (NASDAQ: VERO), a global medical aesthetic technology leader, has scheduled its third quarter fiscal year 2025 financial results release for November 13, 2025, before market opening.
The company will host a conference call at 8:00 a.m. Eastern Time on the same day, featuring a management discussion and Q&A session. Participants can join via phone using access code 13756285 or watch the live webcast on the company's investor relations website. A two-week replay will be available for those unable to attend.
Venus Concept (NASDAQ: VERO) reported Q2 2025 financial results showing total revenue of $15.7 million, down 5% year-over-year but up 15% quarter-over-quarter. U.S. revenue increased by $0.4 million (5%), driven by cash systems sales growth of 23%. The company posted a GAAP net loss of $11.7 million, improved from $19.9 million last year.
Key developments include the sale of Venus Hair business to MHG Co. Ltd for $20 million, multiple equity offerings raising $3.9 million, and debt-to-equity exchanges totaling $17.5 million. The company's gross margin declined to 60.1% from 71.5% in Q2 2024, while operating expenses increased by $1.0 million to $18.5 million.
As of June 30, 2025, Venus Concept had cash and equivalents of $4.9 million and total debt of $34.3 million, compared to $4.3 million and $39.7 million respectively at year-end 2024.
Venus Concept (NASDAQ: VERO), a global medical aesthetic technology leader, has scheduled its second quarter fiscal year 2025 financial results release for August 14, 2025 after market close.
The company will host a conference call at 5:00 p.m. Eastern Time on the same day, featuring a management discussion and Q&A session. Participants can join via phone using access code 13754867 or watch the live webcast on the company's investor relations website. A two-week replay will be available for those unable to attend.
Venus Concept (NASDAQ: VERO), a global medical aesthetic technology leader, has announced a strategic debt-to-equity exchange transaction with Madryn Asset Management. The company exchanged $6.5 million of its subordinated convertible notes for 325,651 shares of Series Y preferred stock.
Following this transaction, Venus Concept's total debt obligations decreased to $34.3 million, representing a 14% reduction compared to the $39.7 million outstanding as of December 31, 2024. The company is currently working on completing its previously announced divestiture of the Venus Hair business while focusing on achieving sustained long-term growth and profitability.